KR102700471B1 - 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 - Google Patents
알파 v 인테그린 억제제로서의 피롤로피라진 유도체 Download PDFInfo
- Publication number
- KR102700471B1 KR102700471B1 KR1020207015957A KR20207015957A KR102700471B1 KR 102700471 B1 KR102700471 B1 KR 102700471B1 KR 1020207015957 A KR1020207015957 A KR 1020207015957A KR 20207015957 A KR20207015957 A KR 20207015957A KR 102700471 B1 KR102700471 B1 KR 102700471B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydrogen
- amino
- mmol
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582693P | 2017-11-07 | 2017-11-07 | |
| US62/582,693 | 2017-11-07 | ||
| PCT/US2018/059157 WO2019094319A1 (en) | 2017-11-07 | 2018-11-05 | Pyrrolopyrazine derivatives as alpha v integrin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200084879A KR20200084879A (ko) | 2020-07-13 |
| KR102700471B1 true KR102700471B1 (ko) | 2024-08-28 |
Family
ID=64362756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207015957A Active KR102700471B1 (ko) | 2017-11-07 | 2018-11-05 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11292802B2 (https=) |
| EP (1) | EP3707142B1 (https=) |
| JP (1) | JP7291696B2 (https=) |
| KR (1) | KR102700471B1 (https=) |
| CN (1) | CN111433207B (https=) |
| AU (1) | AU2018365793A1 (https=) |
| BR (1) | BR112020008893A2 (https=) |
| CA (1) | CA3081805A1 (https=) |
| EA (1) | EA202091136A1 (https=) |
| ES (1) | ES2904645T3 (https=) |
| IL (1) | IL274425A (https=) |
| MX (1) | MX2020004455A (https=) |
| SG (1) | SG11202004077WA (https=) |
| WO (1) | WO2019094319A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102700471B1 (ko) * | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| US20230060422A1 (en) * | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| CA2309204A1 (en) | 1997-11-26 | 1999-06-03 | Dupont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists |
| AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2004521079A (ja) | 2000-08-29 | 2004-07-15 | ファルマシア・コーポレーション | アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物 |
| CA2436130A1 (en) * | 2001-01-29 | 2002-08-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted indoles and their use as integrin antagonists |
| EP1592421A1 (en) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| JP2011184298A (ja) | 2008-06-02 | 2011-09-22 | Sanwa Kagaku Kenkyusho Co Ltd | 新規化合物及びその医薬用途 |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| KR102700471B1 (ko) * | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
-
2018
- 2018-11-05 KR KR1020207015957A patent/KR102700471B1/ko active Active
- 2018-11-05 EA EA202091136A patent/EA202091136A1/ru unknown
- 2018-11-05 JP JP2020524801A patent/JP7291696B2/ja active Active
- 2018-11-05 WO PCT/US2018/059157 patent/WO2019094319A1/en not_active Ceased
- 2018-11-05 BR BR112020008893-5A patent/BR112020008893A2/pt not_active Application Discontinuation
- 2018-11-05 ES ES18804882T patent/ES2904645T3/es active Active
- 2018-11-05 SG SG11202004077WA patent/SG11202004077WA/en unknown
- 2018-11-05 CN CN201880071717.1A patent/CN111433207B/zh active Active
- 2018-11-05 MX MX2020004455A patent/MX2020004455A/es unknown
- 2018-11-05 EP EP18804882.1A patent/EP3707142B1/en active Active
- 2018-11-05 AU AU2018365793A patent/AU2018365793A1/en not_active Abandoned
- 2018-11-05 CA CA3081805A patent/CA3081805A1/en not_active Abandoned
- 2018-11-05 US US16/761,286 patent/US11292802B2/en active Active
-
2020
- 2020-05-04 IL IL274425A patent/IL274425A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
Non-Patent Citations (1)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Letters, 1995, Vol. 5, pp.475-480. |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202004077WA (en) | 2020-05-28 |
| CA3081805A1 (en) | 2019-05-16 |
| AU2018365793A1 (en) | 2020-06-18 |
| ES2904645T3 (es) | 2022-04-05 |
| WO2019094319A1 (en) | 2019-05-16 |
| CN111433207B (zh) | 2023-07-25 |
| EA202091136A1 (ru) | 2020-07-29 |
| BR112020008893A2 (pt) | 2020-10-13 |
| US20210163501A1 (en) | 2021-06-03 |
| JP7291696B2 (ja) | 2023-06-15 |
| EP3707142A1 (en) | 2020-09-16 |
| EP3707142B1 (en) | 2021-12-08 |
| MX2020004455A (es) | 2020-07-24 |
| CN111433207A (zh) | 2020-07-17 |
| IL274425A (en) | 2020-06-30 |
| US11292802B2 (en) | 2022-04-05 |
| JP2021502358A (ja) | 2021-01-28 |
| KR20200084879A (ko) | 2020-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102700471B1 (ko) | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 | |
| US11639353B2 (en) | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | |
| KR102785137B1 (ko) | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 | |
| KR102506327B1 (ko) | αV 인테그린 길항제로서의 인다졸 유도체 | |
| US10717736B2 (en) | Pyrrole amides as alpha V integrin inhibitors | |
| KR102505629B1 (ko) | 알파 v 인테그린 억제제로서의 3-치환된 프로피온산 | |
| KR102913125B1 (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| JP2020505327A5 (https=) | ||
| US11980609B2 (en) | LPA receptor antagonists and uses thereof | |
| CN106852142A (zh) | 作为醛固酮合酶抑制剂的螺二胺衍生物 | |
| JP2019537603A (ja) | アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン | |
| JP7365332B2 (ja) | Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物 | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| WO2026048766A1 (ja) | 多環性化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200603 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211105 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240122 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240527 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240826 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240826 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |